KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Assets (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Non-Current Assets data on record, last reported at $656.1 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 17.05% year-over-year to $656.1 million; the TTM value through Dec 2025 reached $1.3 billion, up 388.35%, while the annual FY2025 figure was $656.1 million, 17.05% down from the prior year.
  • Non-Current Assets reached $656.1 million in Q4 2025 per EBS's latest filing, down from $674.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.0 billion in Q4 2022 and bottomed at -$706.8 million in Q1 2025.
  • Average Non-Current Assets over 5 years is $1.0 billion, with a median of $1.4 billion recorded in 2022.
  • Peak YoY movement for Non-Current Assets: tumbled 139.48% in 2024, then surged 206.59% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $1.7 billion in 2021, then grew by 15.88% to $2.0 billion in 2022, then plummeted by 41.53% to $1.1 billion in 2023, then tumbled by 30.84% to $791.0 million in 2024, then decreased by 17.05% to $656.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $656.1 million in Q4 2025, $674.1 million in Q3 2025, and $697.6 million in Q2 2025.